At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 802 enrolled
Drug / intervention
celecoxib +1 moredrug
Likely dose
celecoxib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Six Week Double-Blind, Randomized, Multicenter Comparison Study Of The Analgesic Effectiveness Of Celecoxib 200 Mg BID Compared To Tramadol Hydrochloride 50 Mg QID In Subjects With Chronic Low Back Pain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Apr 21, 2008·Updated Feb 21, 2021
In Brief
A Phase 3 clinical trial evaluating celecoxib and tramadol HCL for Low Back Pain. Completed, enrolled 802 participants across 60 sites.
Detailed Summary
To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLow Back Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedApr 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.2 years ago
Interventions
celecoxibdrug
200 mg capsules BID for 6 weeks
tramadol HCLdrug
50 mg capsules QID for 6 weeks